fbpx

Vaccines and infectious diseases

Meridian is a leader in high-volume vaccine trials and research programs that require hard-to-reach patients.

The majority of the world’s leading Sponsors and CROs have made Meridian a strategic partner for their infectious disease research programs. Meridian provides a broad national footprint to support rapid enrollment, even for studies involving sensitive cohorts (e.g., seniors, children, at-risk populations).

Several of Meridian’s principal investigators are also sought after by Sponsors and CROs to guide vaccine-related protocol development. These investigators have had research published in prestigious industry journals, including Vaccine.

Patient Receiving Vaccine
+
Vaccine clinical trials conducted
%
Average enrollment for vaccine trials
k
Participants enrolled into vaccine trials

Therapeutic experience

  • Anthrax
  • Chikungunya
  • C. difficile
  • Cytomegalovirus (CMV)
  • Dengue fever
  • Ebola
  • Encephalitis
  • H1N1, H5N1, and H7N9
    influenza
  • Herpes
  • Human metapneumovirus (hMPV)
  • Human papillomavirus (HPV)
  • Influenza, including pediatric, geriatric, and off-season
  • Lyme disease
  • Meningococcal
  • mRNA vaccines
  • Parainfluenza
  • Pediatric meningitis
  • Pediatric influenza
  • Plague
  • Pneumococcal
  • Rabies
  • Respiratory syncytial virus (RSV), including maternal and pediatric
  • SARS-CoV-2 (COVID-19)
  • Smallpox
  • Type 3 (PIV3)/RSV combo
  • West Nile virus
  • Zika virus

COVID-19 clinical trial performance

In 2020, Meridian supported 30 Phase 2 and 3 trials for vaccines, prophylaxes, diagnostics, and medications.

+
COVID-19 vaccine trial patients enrolled

Milestones

The proven site network for novel vaccine research programs

Across any indication, including anti-infectives and immunologics, Meridian is prepared to support your research program for a novel vaccine, diagnostic, or combination product.

In-house monitoring, quality assurance, and audit support

PBMC processing capabilities and central laboratory support

Government-funded, Phase I, and first-in-human trial experience

2020 Vaccine Industry Excellence (ViE) award winner for Best Clinical Trial Site, Best Clinical Trial Network

Featured vaccine investigators

Brandon Essink, MD, CPI

Brandon Essink, MD, CPI

  • Meridian Chief Medical Officer, Principal Investigator since 2003
  • Frequently selected to lead pioneering vaccine research programs
  • Results from clinical studies frequently published in industry journals (recently in Vaccine)
Keith Vrbicky, MD

Keith Vrbicky, MD

  • Meridian Principal Investigator since 2013 in Norfolk, NE
  • Highly-respected physician in his region; frequently published for expertise in maternal vaccination trials
  • Sought after speaker, prominent figure in research for women's health, pediatrics, vaccines
  • Delivered 13,500+ babies
Andrew Kimball

Connect with Andrew Kimball, VP, Business Development at Meridian

Let's talk about your next trial